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Abstract
Background: To determine the suitability of using the self-controlled case series design to assess improvements in
health outcomes using the effectiveness of beta blockers for heart failure in reducing hospitalisations as the
example.
Methods: The Australian Government Department of Veterans’ Affairs administrative claims database was used to
undertake a self-controlled case-series in elderly patients aged 65 years or over to compare the risk of a heart
failure hospitalisation during periods of being exposed and unexposed to a beta blocker. Two studies, the first
using a one year period and the second using a four year period were undertaken to determine if the estimates
varied due to changes in severity of heart failure over time.
Results: In the one year period, 3,450 patients and in the four year period, 12, 682 patients had at least one
hospitalisation for heart failure. The one year period showed a non-significant decrease in hospitalisations for heart
failure 4-8 months after starting beta-blockers, (RR, 0.76; 95% CI (0.57-1.02)) and a significant decrease in the 8-12
months post-initiation of a beta blocker for heart failure (RR, 0.62; 95% CI (0.39, 0.99)). For the four year study there
was an increased risk of hospitalisation less than eight months post-initiation and significant but smaller decrease
in the 8-12 month window (RR, 0.90; 95% CI (0.82, 0.98)).
Conclusions: The results of the one year observation period are similar to those observed in randomised clinical
trials indicating that the self-controlled case-series method can be successfully applied to assess health outcomes.
However, the result appears sensitive to the study periods used and further research to understand the appropriate
applications of this method in pharmacoepidemiology is still required. The results also illustrate the benefits of
extending beta blocker utilisation to the older age group of heart failure patients in which their use is common
but the evidence is sparse.
Background
Administrative claims databases are being used more
widely around the world for research[1], in particular, in
pharmacoepidemiology. Research to assess the practical
viability of study designs using administrative data in a
variety of contexts is imperative so that policy makers
and health professionals can be more confident in the
conclusions that are made using these data sources.
In pharmacoepidemiological studies it can be difficult
to measure and control for the differences between
patients who were prescribed and not prescribed a med-
icine of interest,[2] due to important potential confoun-
ders not being available in the data for use by
researchers[1,3]. Inadequate control of differences
between groups may lead to confounding in assessing
the association between an exposure and outcome of
interest[1,3]. Traditional observational study designs
such as case-control and cohort studies cannot adjust
for unknown, unmeasured or poorly measured confoun-
ders[4]. The self-controlled case series method is gaining
popularity in pharmacoepidemiology as an alternative
study design to cohort and case-control designs. The
main advantage of this method is that it minimises con-
founding due to its within-person design, where the
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patient acts as their own control [5,6]. The within per-
son design controls implicitly for fixed known and
unknown confounders that do not vary over time, such
as genetic and socio-economic factors. Other time vary-
ing confounders such as age can be adjusted within the
model [5,6].
The self controlled case series design includes only
those individuals who have had an outcome of interest.
A comparison is made between the rate of events during
periods of exposure and non-exposure to the drug of
interest. Confounding by indication can also be assessed
and controlled for in this method through the use of
pre-exposure risk periods. Confounding by indication is
present if patient characteristics alter the likelihood of
being prescribed a medicine and are at the same time
related to the probability of an outcome[7].
The self controlled case-series design has been used to
assess the adverse events of medicines[2,8-14] and has
been identified as a potential tool for post-marketing
surveillance of medicines[12]. To date, this method has
not been used to assess the effectiveness of medicines.
In this study we used the example of beta-blockers for
heart failure to assess whether the self-controlled case
series method can be applied to study the effectiveness
of medicines. The effectiveness of beta-blockers in heart
failure was chosen as a test case as there is evidence
from randomised controlled trials that beta blockers
reduce hospitalisations for heart failure[15] and the out-
come of reduced hospitalisations has been observed in
short term trials of twelve months or less.
Randomised controlled trial evidence has led to beta
blockers being recommended in current clinical guide-
lines as first line agents for patients with symptomatic
or advanced chronic heart failure [16]. Clinical trials of
beta blockers for heart failure predominately recruited
participants who were on average in their early sixties,
which is about 10-15 years younger than those living in
the community with heart failure[17]. Thus evidence for
the efficacy of beta-blockers for heart failure in the
elderly is limited. Few observational studies have been
conducted in the elderly with heart failure and con-
founding by indication being identified as possible lim-
itations of these studies[18].
The objective of this study was to determine the suit-
ability of using the self-controlled case series design to
assess improvements in health outcomes using the
example of effectiveness of beta-blockers for heart fail-
ure in reducing the risk of hospitalisation for heart
failure.
Methods
The data source for this study was the Australian
Department of Veterans’ Affairs (DVA) administrative
claims databases. This database is not publicly available
and was provided by the Department of Veterans Affairs
as part of the delivery of the Veterans’ Medicines Advice
and Therapeutics Education Services (Veterans’
MATES) project. DVA claims data contain records of
prescription medicines dispensed under the Repatriation
Pharmaceutical Benefits Scheme, medical and allied
health services and hospital admissions provided to
veterans for whom DVA pays a subsidy. The treatment
population is approximately 310 000 veterans, and there
are approximately 100 million pharmacy records, 200
million medical and allied health service records and
over 6 million hospital admission records. A client file is
maintained by DVA which includes data on sex, date of
birth, date of death and family status.
A self controlled case series study was conducted.
Since heart failure is a disease that is not stable over
time and can cause patients to deteriorate quickly, two
studies with differing follow-up times were undertaken.
The one year period was chosen as this is similar to
the randomised controlled trial periods and is also
likely to be a period where heart failure is more stable.
The four year period was chosen to determine if the
method can assess effectiveness over a longer time per-
iod. The two observation periods used were a one year
period starting 1st July 2005 and a four year period
starting 1st July 2002 and with both studies ending on
the 30th June 2006. All veterans who had a hospitalisa-
tion with a primary diagnosis of heart failure (ICD-10
I500, I501, I509) during the observation period, who
were aged 65 years or over at study entry and who
were eligible for all health services subsided by the
Department of Veterans’ Affairs were included. For
these veterans, prescription data on beta blockers for
heart failure (bisoprolol, carvedilol, and metoprolol
succinate) were identified. These beta blockers are only
available under a prior authorization process where the
prescribing physician must indicate at the time of pre-
scription that the patients have the diagnosis of heart
failure. Analysis of the data showed that 75% of veter-
ans returned for a refill prescription within 36 days, so
the duration of each prescription was assumed to be
36 days.
Only incident users of beta blockers for heart failure
were included. Those who had been dispensed a beta
blocker for heart failure in the 12 months prior to study
start were excluded. Heart failure is a progressive dis-
ease that can cause an increase in the risk of a hospital
admission for heart failure over time regardless of treat-
ment. Since this study includes long indefinite risk peri-
ods it maybe more prone to possible confounding
between age and exposure effects[6]. This possible con-
founding is reduced in this study by the inclusion of
veterans who had a hospitalisation for heart failure but
were not exposed to a beta blocker [6]. These patients
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were expected to contribute information on the impact
of age on the risk of the outcome.
Person time was divided into risk periods; 1 day-2
weeks, 2-4 weeks, 1-4 months, 4-8 months, 8-12 months
and for the four year study period >12 months post beta
blocker initiation. Four consecutive 2 week pre-exposure
risk periods were included prior to beta blocker initia-
tion to remove the effect of confounding by indication
from the unexposed time. The actual day of the pre-
scription was excluded because in cases where the heart
failure hospitalisation occurred on the same day it was
not possible to determine which occurred first. All
remaining time was considered unexposed to a beta-
blocker for heart failure, including all the follow-up time
of an unexposed individual and was used as the baseline
comparison period (Figure 1).
In each risk period, the cumulative number of hospita-
lisations was divided by the person years at risk and
these were compared to the baseline period. If a veteran
was re-hospitalised within 30 days, the subsequent hos-
pitalisation(s) were excluded as they were considered to
be related, and part of the same episode [6]. Rate ratios
were calculated using conditional Poisson regression,
with results presented as adjusted rate ratios and 95%
confidence intervals. While the self-controlled case
series method controls implicitly for fixed covariates,
there may be important confounders/covariates that
change over time within person that should be con-
trolled for in the analysis. Therefore, adjustment was
made for age at heart failure hospitalisation[8], study
month and time-varying covariates which were assessed
quarterly; co-morbidities using the Australian adaption
of Rx-Risk-V[19], number of prescribers, admission into
aged care and prescription of frusemide, ACE/A2RB,
digoxin and aldosterone antagonists. Sensitivity analyses
were undertaken excluding non-exposed patients and
the one year study was conducted over different calen-
dar periods to assess the effects of calendar time. All
analyses were performed using SAS version 9.12 (SAS
Institute, Cary, NC).
Results
In the one year observation period there were 3,450
veterans who had at least one hospitalisation for heart
failure and of those 645 (19%) were initiated on a beta
blocker for heart failure. There were 12,682 patients
who had at least one hospitalisation for heart failure in
the four year study period, with 3,276 (26%) initiated on
a beta blocker for heart failure. Table 1 contains the
characteristics of the study population. For both
























Figure 1 A graphical representation of the self-controlled case-series study design for patients (a) exposed to a beta-blocker (b)
unexposed to a beta-blocker.
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observation periods the length of follow-up and age at
first exposure was similar for the exposed and unex-
posed groups.
The results of the one year observation showed that in
the post-exposure risk periods there was a significant
increased risk before 2 weeks, a non-significant decrease
4-8 months and significant decrease in hospitalisations
for heart failure 8-12 months post-initiation of beta
blocker compared to baseline. In the pre-exposure risk
periods there was a significant increase less than 6
weeks and a non-significant difference 6-8 weeks (table
2).
For the four year observation period, the post-expo-
sure risk periods indicated that before eight months
post initiation of a beta blocker there was an increased
risk of hospitalisation for heart failure and a significant
decrease greater than eight months post initiation com-
pared to the baseline period. In all pre-exposure risk
periods there was a statistically significant increased risk
of having a hospitalisation for heart failure compared to
the baseline period (table 3).
In both studies, the risk estimates for the models
adjusted for age and study month were comparable to
those observed in the models adjusted for all confoun-
ders (tables 2, 3). The results of all one year sensitivity
analyses, which are not presented, showed the same
trends as those observed in the one year period that is
shown.
Discussion
This study using a self controlled case-series design,
found variable results from the two different time peri-
ods, however, results from both studies suggest that
long-term treatment with beta-blockers for heart failure
is associated with a significant reduction in the risk of
hospitalisation due to heart failure. The results from the
one year study period are comparable with those seen in
a meta-analysis[15] which found a reduction in hospital
admissions for heart failure for patients randomised to
receive beta blockers compared to controls (OR, 0.63;
95% CI (0.56, 0.71) P < 0.0001)[15]. The average length
of treatment for the studies included in the meta-ana-
lyses was 11 months[15]. This compares with the results
seen in the later risk periods of our one year study per-
iod where there was a non-significant decrease in heart
failure hospitalisations 4-8 months (RR, 0.76; 95% CI
(0.57-1.02)) and a significant decrease >8 months, post-
initiation of a beta blocker compared to baseline (RR,
0.62; 95% CI (0.39, 0.99)). The results of the longer four
year study showed a statistically significant decrease in
Table 1 Characteristics of study subjects by period of observation
Exposure Status Number of Subjects Follow-up Years* Duration of exposure* Age at first hospitalisation* Age at first exposure*
1 Year observation period
Exposed 645 0.5(0.3,0.7) 0.3(0.1,0.6) 81(79,84) 81(78,84)
Unexposed 2805 0.5(0.3,0.8) 82(79,86)
4 Year observation period
Exposed 3276 2.0(1.1,3.0) 0.8(0.2,1.8) 83(80,86) 81(78,84)
Unexposed 9406 1.7(1.0,3.0) 83(80,87)
*Median (q1, q3)
Table 2 Case-series adjusted analysis for 1 year observation period
Risk Periods Number of Hospitalisations Person-Years Adjusted age and study month only RR(95% CI) Adjusted* RR(95% CI)
Baseline unexposed Period
Unexposed 3275 2660 1.00 (1.00 - 1.00) 1.00 (1.00 - 1.00)
Pre-exposure to a beta blocker for heart failure
6-8 weeks 18 22 1.37 (0.93 - 2.01) 1.29 (0.88 - 1.89)
4-6 weeks 52 23 3.74 (2.90 - 4.82) 3.47 (2.70 - 4.46)
2-4 weeks 87 24 5.85 (4.72 - 7.26) 4.97 (4.02 - 6.16)
1 day-2 weeks 255 25 15.98 (13.51 - 18.91) 12.72 (10.74 - 15.07)
Post-exposure to a beta blocker for heart failure
1 day-2 weeks 46 25 2.85 (2.18 - 3.72) 2.21 (1.70 - 2.88)
2-4 weeks 25 23 1.63 (1.16 - 2.29) 1.29 (0.92 - 1.80)
1-4 months 94 107 1.34 (1.08 - 1.67) 1.18 (0.94 - 1.47)
4-8 months 46 76 0.78 (0.58 - 1.04) 0.76 (0.57 - 1.02)
8-12 months 15 24 0.66 (0.42 - 1.05) 0.62 (0.39 - 0.99)
*Adjusted for age at heart failure hospitalisation[8], study month and time-varying covariates which were assessed quarterly; co-morbidities using the Australian
adaption of Rx-Risk-V[19], number of prescribers, admission into aged care and prescription of frusemide, ACE/A2RB, digoxin and aldosterone antagonists
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hospital admissions only greater than 8 months post
initiation of a beta blocker (8-12 months: RR, 0.90; 95%
CI (0.82, 0.98): >12 months: RR, 0.61; 95% CI (0.57,
0.66)) and by contrast an increased risk in the 4 to 8
month period post initiation of a beta-blocker. Com-
pared to the 1 year results, the decrease was seen later
and the comparable risk estimates approximately a third
smaller.
Our study shows that the length of observation per-
iod chosen for the self-controlled case series is an
important factor to consider when utilising this
method for effectiveness research. In the four year
study beta blockers appear to be less effective when
compared to the one year period. This may be due to
several factors including a difference in the proportion
of the unexposed person-years for exposed subjects
prior to the prescription of a beta blocker in the 4 year
compared to the one year period (93% and 85% respec-
tively). Prior to exposure to beta-blockers, patients are
likely to be healthier as initiation of beta blockers
usually occurs when a patient’s heart failure cannot be
controlled with angiotensin-converting enzyme inhibi-
tors alone or their symptoms have progressed to
advanced heart failure[16]. Due to heart failure being a
disease with a short life expectancy and an increased
risk of re-hospitalisation over time, it is likely that the
four year results are less reliable.
For both our study periods, we found that the risk of
hospitalisation for heart failure was increased in the first
weeks following treatment initiation. This finding was
not unexpected as an RCT assessing carvedilol found
that initiation of beta blockers caused worsening heart
failure in 5.9% of study participants during the two
week run-in period[20].
The self-controlled case series method was designed
to evaluate the association between a transient exposure
and an acute event[5,6]. However, it may be applied to
non-acute events that occur long after initial exposure
[5,6]. When long risk periods are used, which is the case
in this example confounding between age and exposure
effects can be more pronounced. Simulation studies
have found that inclusion of an unexposed group elimi-
nates this[5,6]. Therefore, in our studies we have
included an unexposed group.
For both study lengths, the unadjusted and adjusted
results were similar which is to be expected as the main
advantage of the self-controlled case series method is its
within-subject design that minimises confounding by
controlling implicitly for fixed known and unknown
confounders [5,6].
The self-controlled case-series method has three key
assumptions[5,6]. The first assumption states that recur-
rent outcome events must be independent, that is, the
occurrence of one event must not alter the probability
of a subsequent event occurring [5,6]. In our example,
once a person has had a hospitalisation for heart failure
their short-term risk of experiencing another may be
increased. Therefore, hospitalisations may cluster within
independent episodes, usually within 30 days of admis-
sion. One strategy to deal with this was to only include
the first hospital admission of each episode[6]. The sec-
ond assumption is that the occurrence of an event must
not alter the probability of subsequent exposures[5,6].
This assumption is rarely, if ever, met when assessing
the effectiveness of medicines to prevent hospitalisa-
tions. This is because medicines are routinely initiated
during a hospital stay. This is a form of confounding by
indication. This problem can be assessed and controlled
Table 3 Case-series analysis for 4 year observation period
Risk Periods Number of Hospitalisations Person-Years Adjusted age and study month only RR(95% CI) Adjusted* RR(95% CI)
Baseline unexposed Period
Unexposed 13541 34944 1.00 (1.00 - 1.00) 1.00 (1.00 - 1.00)
Pre-exposure to a beta blocker for heart failure
6-8 weeks 137 147 2.22 (2.00 - 2.45) 2.24 (2.02 - 2.48)
4-6 weeks 237 148 3.79 (3.50 - 4.11) 3.82 (3.52 - 4.14)
2-4 weeks 380 149 5.93 (5.54 - 6.34) 5.92 (5.54 - 6.34)
1 day-2 weeks 872 150 13.04 (12.38 - 13.73) 12.95 (12.29 - 13.63)
Post-exposure to a beta blocker for heart failure
1 day-2 weeks 190 149 2.75 (2.52 - 3.01) 2.74 (2.51 - 3.00)
2-4 weeks 156 145 2.27 (2.06 - 2.50) 2.27 (2.06 - 2.50)
1-4 months 488 734 1.71 (1.61 - 1.82) 1.68 (1.58 - 1.79)
4-8 months 322 685 1.21 (1.12 - 1.30) 1.18 (1.10 - 1.27)
8-12 months 212 535 0.93 (0.85 - 1.02) 0.90 (0.82 - 0.98)
>12 months 458 1358 0.65 (0.60 - 0.70) 0.61 (0.57 - 0.66)
*Adjusted for age at heart failure hospitalisation[8], study month and time-varying covariates which were assessed quarterly; co-morbidities using the Australian
adaption of Rx-Risk-V[19], number of prescribers, admission into aged care and prescription of frusemide, ACE/A2RB, digoxin and aldosterone antagonists
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for through the use of pre-exposure risk periods. If pre-
exposure risk periods are not removed from the baseline
unexposed time, then the relative risk will be biased
towards the null[6], as the risk in the unexposed period
would be inflated. The final assumption is that the
occurrence of the event of interest must not censor or
affect the observation period[5,6]. This assumption
would frequently be violated when the outcome event is
a hospital admission. This is due to the fact that the
hospitalisation will likely increase the probability of
death. However, Farrington et al[21], have shown that
this method may be robust to failure of this assumption.
One of the main strengths of this study was the use of
the self-controlled case series design which has the abil-
ity to overcome confounding issues that can affect
cohort and case-control studies, in particular confound-
ing by indication. Pre-exposure risk periods for both
studies showed significant increases in the rate of hospi-
talisations prior to being exposed to a beta blocker for
heart failure, demonstrating that the likelihood of being
prescribed a beta blocker increases after an event of a
heart failure hospitalisation, confirming that confound-
ing by indication is present.
Conclusions
The self-controlled case series method has not been
used in pharmacoepidemiological research, to address
questions about the effectiveness of medicines. There-
fore, the findings of this study are important in gaining
knowledge on the usefulness of this study design for
this purpose. This study demonstrated that the choice
of observation period is important particularly when the
underlying disease under study is not stable over time.
Changes in a patient’s disease severity make it difficult
to adequately assess the effectiveness of a medicine over
a long period of time. Further research is necessary to
develop guidelines for the appropriate use of the self-
controlled case series design and to understand when it
can be applied most effectively. The results of this study
when we restricted to a one year observation period
were consistent with those observed in randomised clin-
ical trials indicating that the self-controlled case-series
method can be successfully applied to assess health out-
comes using a claims database. The results also illustrate
the benefits of extending beta blocker utilisation to the
older age group of heart failure patients in which their
use is common but the evidence is sparse.
Abbreviations
(DVA): Department of Veterans’ Affairs; (RCT): randomised clinical trial.
Acknowledgements and funding source
The research was funded by the Australian Government Department of
Veterans’ Affairs (DVA) as part of the delivery of the Veterans’ Medicines
Advice and Therapeutics Education Services (Veterans’ MATES) project. DVA
reviewed this manuscript prior to submission, but played no role in the
design, execution, analysis or interpretation of data, or writing of the paper.
Author details
1Data Management and Analysis Centre, Discipline of Public Health,
University of Adelaide, South Australia, 5000, Australia. 2School of Pharmacy
and Medical Sciences, Quality Use of Medicines and Pharmacy Research
Centre; Sansom Institute, University of South Australia, South Australia, 5000,
Australia. 3School of Medicine and Public Health, Faculty of Health, University
of Newcastle, NSW 2308 Australia.
Authors’ contributions
ENR participated in the design of the study, performed the statistical
analysis, interpreted the data and drafted the manuscript. EER participated in
the design, interpretation and to draft the manuscript. BE participated in the
design, interpretation and to draft the manuscript. NP participated in the
design, interpretation and to draft the manuscript. PR participated in the
design and interpretation of the data. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 10 March 2011 Accepted: 18 July 2011
Published: 18 July 2011
References
1. Schneeweiss S, Avorn J: A review of uses of health care utilization
databases for epidemiologic research on therapeutics. Journal of Clinical
Epidemiology 2005, 58:323-337.
2. Douglas IJ, Evans SJ, Pocock S, Smeeth L: The Risk of Fractures Associated
with Thiazolidinediones: A Self-controlled Case-Series Study. PLoS
Medicine 2009, 6(9):e1000154.
3. Brookhart MA, Sturmer T, Glynn R, Rassen J, Schneeweiss S: Confounding
Control in Healthcare Database Research Challenges and Potential
Approaches. Med Care 2010, 48:S114-S120.
4. Dobre D, van Veldhuisen DJ, deJongste MJL, van Sonderen E,
Klungel OH, Sanderman R, Ranchor AV, Haaijer-Ruskamp FM: The
contribution of observational studies to the knowledge of drug
effectiveness in heart failure. British Journal of Clinical Pharmacology
2007, 64(4):406-414.
5. Whitaker HJ, Hocine MC, Farrington CP: The methodology of self-
controlled case series studies. Statistical Methods in Medical Research 2009,
18:7-26.
6. Whitaker HJ, Farrington CP, Spiessens B, Musonda P: Tutorial in
Biostatistics: The self-controlled case series method. Statistics in Medicine
2005, 0:1-31.
7. Strom B, Miettinen O, Melmon K: Post-Marketing Studies of Drug Efficacy:
How? Am J Med 1984, 77:703-708.
8. Hubbard R, Lewis S, Smith C, Godfrey C, Smeeth L, Farrington P, Britton J:
Use of nicotine replacement therapy and the risk of acute myocardial
infarction, stroke and death. Tobacco Control 2005, 14:416-421.
9. Douglas IJ, Smeeth L: Exposure to antipsychotics and risk of stroke: self
controlled case series study. BMJ 2008, 337(a1227):1-5.
10. Gibson J, Hubbard R, Smith C, Tata L, Britton J, Fogarty A: Use of the Self-
controlled Analytical Techniques to Assess the Association Between Use
of Prescription Medications and the Risk of Motor Vehicle Crashes. Am J
of Epidemiol 2009, 169(6):761-768.
11. Pratt N, Roughead E, Ramsay E, Salter A, Ryan P: Risk of Hospitalization for
Stroke Associated with Antipsychotic Use in the Elderly: A Self-
Controlled Case Series. Drugs Aging 2010, 27(11):885-893.
12. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L: Post-marketing
assessment of the saftey of strontium ranelate; a novel case-only
approach to the early detection of adverse drug reactions. Br J Clin
Pharmacol 2008, 66(5):689-694.
13. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L: Oral
Bisphosphonates and Risk of Atrial Fibrillation and Flutter in Women: A
Self-Controlled Case-Series Saftey Analysis. PLoS One 2009, 4(3):e4720.
14. Hippisley-Cox J: Unintended effects of statins in men and women in
England and Wales: population based cohort study using the QResearch
database. BMJ 2010, 340:c2197.
Ramsay et al. BMC Medical Research Methodology 2011, 11:106
http://www.biomedcentral.com/1471-2288/11/106
Page 6 of 7
15. Shibata MC, Flather MD, Wang D: Systematic review of the impact of beta
blockers on mortality and hospital admissions in heart failure. European
Journal of Heart Failure 2001, 3:351-357.
16. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ, Hawkes AL:
Guidelines for the prevention, detection and management of people
with chronic heart failure in Australia 2006. MJA 2006, 185(10):549-556.
17. Krum H: Beta-blockers in chronic heart failure: What have we learned?
What do we still need to know? Current Opinion in Pharmacology 2003, ,
3: 168-174.
18. Sin DD, Finlay A, McAlister FA: The Effects of Beta-blockers on Morbibity
and Mortality in a Population-Based Cohort of 11, 942 Elderly Patients
with Heart Failure. Am J Med 2002, 113:650-656.
19. Vitry A, Wong SA, Roughead E, Ramsay E, Barratt J: Validity of medication-
based co-morbidity indices in the Australian elderly population. Aust N Z
J of Public Health 2009, 33:126-130.
20. Packer M, Bristow M, Cohn J, Colucci W, Fowler M, Gilbert E, Shusterman N:
The Effect of Carvedilol on Morbidity and Mortality in Patients with
Chronic Heart Failure. The New England Journal of Medicine 1996,
334(21):1349-1355.
21. Farrington CPWH: Semiparametric analysis of case series data. Appl Stat
2006, 55(553-94).
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2288/11/106/prepub
doi:10.1186/1471-2288-11-106
Cite this article as: Ramsay et al.: A self-controlled case series to assess
the effectiveness of beta blockers for heart failure in reducing
hospitalisations in the elderly. BMC Medical Research Methodology 2011
11:106.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ramsay et al. BMC Medical Research Methodology 2011, 11:106
http://www.biomedcentral.com/1471-2288/11/106
Page 7 of 7
